Advances in monoclonal antibody therapeutics
A decade ago, and after many efforts to reach their commercial potential and overcome many setbacks, the biopharmaceutical market saw how those once-small players become giants (Amgen, Genentech, Biogen Idec), with the development of first-generation. Now, next-generation antibody-based platforms are gaining a momentum, expecting to impact patient care with the same intensity, especially in the field of precision medicine.
Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, most especially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience.
The development of these new molecular agents, successfully directed to specific cellular targets, is playing a crucial role in the pharmaceutical industry. This trend shows the strong focus of top biopharmaceutical companies on biologics, including monoclonal antibody therapeutics. In this report, the current worldwide status of the research portfolio for monoclonal antibody therapeutics is presented.
This research service discusses the emerging trends in monoclonal antibody therapeutics on a global scale, through a detailed strategic assessment of the industry environment, including:
R&D portfolio and budgetary analysis
Environmental analysis, depicting the key technical challenges, key business, challenges and emerging market needs
Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
Strategic evaluation of R&D portfolio
List of key patents of noteworthy innovations of global participants and a detailed list of key contacts in the field.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook